TEVA

Retail Results Spoil the Day — Monday’s IP Market Recap

A disappointing retail report and mixed results for Citigroup's second quarter weighed on markets Monday, though M&A news sparked life into pharma. More

Swing for the Fences With These 5 Biotech Stocks

If you're prepared for the very high stakes and high risks of biotech investing, these five biotech stocks might be worth your while. More

Investors Bag the Groceries: Thursday’s IP Market Recap

Markets were down as continued worries about Europe and another round of disappointing earnings and guidance pushed prices lower. More

Brutal Day for Banks & Tech — Monday’s IP Market Recap

The broader markets were slammed by news across the Atlantic on Monday, with banks and tech stocks taking the brunt of it. More

CVS, Rite Aid Sue Pfizer, Teva Over Antidepressant

CVS Caremark and Rite Aid have sued Pfizer and Teva accusing the drugmakers of working together to delay generic verisons of Effexor XR. More

Europe’s Woes Slam the U.S.: Wednesday’s IP Market Recap

U.S. markets were roiled from the start of the day by political and economic turbulence in Europe, as stocks traded down from the opening bell through the day. More

Generic Versions of Plavix Get FDA Approval

The U.S. Food and Drug Administration approved generic versions of the best-selling blood thining drug Plavix on Thursday. More